Mannose-6-phosphate receptor mediated gene transfer into muscle cells

• US 20120122801A1
• Filed: 01/12/2012
• Published: 05/17/2012
• Est. Priority Date: 01/05/2005
• Status: Abandoned Application

• Current Assignee: Prosensa Therapeutics
• Original Assignee: Prosensa B.V.
• Inventors: PLATENBURG, Gerard Johannes
• Application Number:
  US13/349,198
• Publication Number:
  US 20120122801A1
• Time in Patent Office: Days
• US Class Current: 514/20.9
• CPC Class Codes: A61K 31/7088 Compounds having three or more nucleosides or nucleotides
• CPC Class Codes: A61P 21/00 Drugs for disorders of the muscular or neuromuscular system
• CPC Class Codes: C07H 15/04 attached to an oxygen atom of the saccharide radical
• CPC Class Codes: C07H 15/08 Polyoxyalkylene derivatives
• CPC Class Codes: C07H 21/00 Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
• CPC Class Codes: C07H 21/02 with ribosyl as saccharide radical
• CPC Class Codes: C07H 21/04 with deoxyribosyl as saccharide radical
• CPC Class Codes: C12N 15/111 General methods applicable to biologically active non-coding nucleic acids
• CPC Class Codes: C12N 15/113 Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing when used in plants C12N15/8218
• CPC Class Codes: C12N 2310/11 Antisense
• CPC Class Codes: C12N 2310/3513 Protein; Peptide
• CPC Class Codes: C12N 2320/32 Special delivery means, e.g. tissue-specific
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material

Abstract

The invention relates to glycoside-compound conjugates for use in antisense strategies and/or gene therapy. The conjugates comprise a glycoside linked to a compound, in which the glycoside is a ligand capable of binding to a mannose-6-phosphate receptor of a muscle cell. For example the cells are muscle cells of a Duchenne Muscular Dystrophy (DMD) patient and the conjugate comprises an antisense oligonucleotide which causes ex on skipping and induces or restores the synthesis of dystrophin or variants thereof.

Claims

1. A conjugate comprising at least one glycoside linked to a compound, characterized by said glycoside being a ligand capable of binding to a mannose-6-phosphate receptor of a muscle cell.

2. The conjugate according to claim 1, wherein said compound is an oligonucleotide or derivative or an equivalent thereof.

3. The conjugate according to claim 2, wherein said oligonucleotide or derivative or equivalent thereof is an RNA, DNA, Peptide Nucleic Acid (PNA), morpholino or Locked Nucleic Acid (LNA).

4. The conjugate according to claim 3, wherein 1) said morpholino derivative or equivalent is a Phosphorodiamidate Morpholino Oligomer (PMO);

2) said oligonucleotide derivative is a 2′

-O-methyl RNA;

or

     3) said oligonucleotide or derivative or equivalent thereof is in an antisense orientation.

5. The conjugate according to claim 4, wherein 3) said oligonucleotide or derivative or equivalent thereof is causing exon skipping in the human dystrophin gene and inducing or restoring the synthesis of dystrophin or variants thereof.

6. The conjugate according to claim 5, wherein in 3) said oligonucleotide or derivative or equivalent thereof comprises at least 20 nucleotides.

7. The conjugate according to claim 1, wherein said mannose-6-phosphate receptor is an insulin-like growth factor II/mannose-6-phosphate receptor (IGF-II/MPR).

8. The conjugate according to claim 1, wherein said glycoside is a mono-, di- or tri-saccharide, or any higher order saccharide, and wherein said saccharide comprises at least one mannose-6-phosphate (M6P) residue.

9. The conjugate according to claim 2, wherein the conjugate comprises one, two, three or more glycosides, wherein said glycosides comprise at least one mannose 6 phosphate residue.

10. The conjugate according to claim 1, wherein said glycoside is linked to said compound via a labile spacer that can be cleaved intracellularly.

11. A method selected from the group consisting of:

(a) a method for delivering a compound into the nucleus of cells comprising an insulin-like growth factor II/mannose-6-phosphate receptor (IGF-II/MPR), characterized by contacting a glycoside-compound conjugate according to claim 1 with said cells;

(b) a method for treating muscle diseases selected from Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), spinal muscular atrophy (SMA), Bethlem myopathy, myotubular myopathy, limb-girdle muscular dystrophy 2A and 2B, Miyoshi myopathy, myotonic dystrophy, lysosomal storage disorders and merosin deficient muscular dystrophy, characterized by contacting muscle cells of patients with a conjugate according to claim 1;

(c) a method for inducing the synthesis or functioning of any RNA species in muscle cells, characterized by contacting said cells with a glycoside-compound conjugate according to claim 1, whereby said compound inhibits or reduces the activity of RNAs or proteins repressing the synthesis or functioning of said RNA species;

(d) a method for inhibiting or reducing the synthesis or functioning of any RNA species in muscle cells which causes disease or predisposition of disease, characterized by contacting said muscle cells with a glycoside-compound conjugate according to claim 1, whereby said compound inhibits the synthesis or functioning of said RNA species;

(e) a method for delivering a vaccine into muscle cells, characterized by contacting muscle cells with a glycoside-compound conjugate according to claim 1, wherein said compound is a vaccine; and

(f) a method for blocking or stimulating any RNA that can lead to improved performance of heart, respiratory or skeletal muscles with the aim to ameliorate the progression of muscle disease, by contacting muscle cells with a glycoside-compound conjugate according to claim 1.

12. The method according to claim 11, wherein in (a) said cells are muscle cells of a Duchenne Muscular Dystrophy (DMD) patient or Becker Muscular Dystrophy (BMD) and wherein said compound is an antisense oligonucleotide which causes exon skipping and induces or restores the synthesis of dystrophin or variants thereof.

13. The conjugate according to claim 1, further comprising a marker.

14. A method for in vivo or in vitro diagnostic tests, characterized by contacting a conjugate according to claim 13 with muscle cells and detecting directly or indirectly the presence or absence of said marker.

15. A method for increasing body muscle mass, by contacting muscle cells with a glycoside-compound conjugate according to claim 2, wherein said oligonucleotide for instance inhibits myostatin production.